Novartis Finds Targeted Prostate Cancer Therapy Helps Patients

Novartis AG said a prostate treatment that delivers radiation to specifically targeted cancer cells helped patients in a study that the Swiss drugmaker will use for US regulatory approval.

The precision medicine, called Pluvicto, showed an effect on a form of survival without the disease worsening in patients who had already been treated with androgen-receptor pathway inhibitor therapy and whose prostate cancer had spread.